|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cost of sales (note 14) | |||||
| Research and development | |||||
| General and administrative | |||||
| Selling and distribution | |||||
| Total operating expenses | |||||
| Net finance expense (income) (note 15) | |||||
| Loss before income taxes | |||||
| Income taxes | |||||
| Income tax (recovery) expense (note 16) | |||||
| Deferred tax expense (note 16) | |||||
| Foreign currency translation adjustment - net of tax | |||||
| Net loss and comprehensive loss for the year | |||||
| Basic loss per common share | |||||
| Revenue | |||||
| Recurring - non-capital | |||||
| Capital equipment | |||||
| Total revenue | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Operating expenses | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other (income) expenses | |||||
| Net finance (income) expense | |||||
| Net foreign exchange (gain) loss | |||||
| Total other (income) expenses | |||||
| Net loss before income taxes | |||||
| Income tax expense (note 13) | |||||
| Deferred tax (recovery) expense (note 13) | |||||
| Total income tax (recovery) expense | |||||
| Net loss attributed to shareholders for the year | |||||
| Other comprehensive (income) loss | |||||
| Item that may be reclassified to (income) loss | |||||
| Foreign currency translation adjustment | |||||
| Net loss and other comprehensive loss for the year | |||||
| Loss per share (note 14) | |||||
| Basic net loss per common share (in dollars per share) | |||||
| Diluted net loss per common share (in dollars per share) | |||||
| Basic weighted average common shares outstanding (in shares) | |||||
| Diluted weighted average common shares outstanding (in shares) | |||||
Loading...